Intravenous diazoxide and oral furosemide in hypertensive patients with azotemia initially increased BUN and creatinine, but long-term therapy reduced BUN by 24 mg/dL and creatinine by 2.8 mg/dL.
Observational (n=25)
By giving diazoxide intravenously and furosemide orally the diastolic blood pressure was kept under 110 mm Hg and the urinary output over 1 L/day for a 2-week period in 25 hypertensive patients with azotemia. During the first 2 weeks of treatment three patients died. Although the 40% decrease in mean arterial pressure in the remaining patients was associated with immediate improvement in the cardiovascular status, for example, clearing of congestive heart failure and papilledema, there was a 19% average increase in BUN and 17% average increase in serum creatinine values. Three months later, however, maintenance of the reduced arterial pressure was associated with average reductions of 24 mg/100 ml in BUN and of 2.8 mg/100 ml in serum creatinine below control values. Each of the patients who remained on therapy continued to do well. Twenty-six months later six additional patients had died. In the remaining 16 patients the average mean arterial pressure was 117 mm Hg; papilledema had cleared; the average concentration of BUN was 22 mg/100 ml; the average serum creatinine was 1.8 mg/100 ml.
Mroczek et al. (Mon,) conducted a observational in Hypertensive patients with azotemia (n=25). Intravenous diazoxide and oral furosemide was evaluated on Blood pressure, renal function, and mortality. Intravenous diazoxide and oral furosemide in hypertensive patients with azotemia initially increased BUN and creatinine, but long-term therapy reduced BUN by 24 mg/dL and creatinine by 2.8 mg/dL.